Medicare AdvantageCoverageMedium impact
Multianalyte Assays with Algorithmic Analyses for Cancer Indications - Medicare Advantage (Revised)
Humana·Oncology, Gastroenterology, OB-GYN +1 more·Medicare Advantage
Effective date
May 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has revised their policy for Multianalyte Assays with Algorithmic Analyses for Cancer Indications, effective May 1, 2026. This policy covers specialized cancer diagnostic tests like OvaSuite (ovarian cancer risk), PancraGEN (pancreatic cyst malignancy risk), and TissueCypher Barrett's Esophagus Assay, with coverage determined by CMS guidelines and MolDX registry requirements.
Action Required
Before May 1, 2026: Billing team should review current claims for multianalyte cancer assays (OvaSuite, PancraGEN, TissueCypher) to ensure compliance with Medicare Advantage requirements. Verify that these tests meet CMS analytical and clinical validity standards through applicable LCDs/LCAs for your jurisdiction. Update prior authorization workflows if required by local MAC guidelines.